Singapore and China Sign Memorandum of Understanding to Renew Commitment in Enhancing Regulatory Collaboration on Health Products

Singapore's Health Sciences Authority (HSA) and China's National Medical Products Administration (NMPA) signed a Memorandum of Understanding (MOU) on 11 May 2026 in Beijing, China, to renew their commitment in health products regulatory collaboration, so as to support faster access to new and innovative health products for patients and healthcare systems in both countries. The renewed MOU expands the scope of regulatory cooperation into new emerging areas such as cell, tissue and gene therapy products, and strengthens collaboration to explore building facilitative regulatory pathways, pilot innovative schemes, capacity building and staff exchanges.  

2         The expanded partnership is expected to strengthen regulatory convergence and enhance opportunities for industry engagement, potentially enabling more efficient development, evaluation and market access pathways for the new innovative therapeutics and medical technologies. Both agencies will also continue to collaborate on the exchange of regulations, information and best practices, and potential joint efforts to combat counterfeit, falsified and substandard health products, including collaboration on inspections of manufacturing facilities and testing.

3         The renewal and expansion in the scope of the MOU, signed by Adjunct Professor (Dr) Raymond Chua, Chief Executive Officer of HSA, and Mr Huang Guo, Commissioner of NMPA, seeks to expand on the 2021 agreement, which covered the regulation of chemical drugs, active pharmaceutical ingredients, biological products, traditional Chinese medicines, medical devices and cosmetics. Building on the 2021 agreement, the renewed MOU expands the scope of collaboration to encompass cell, tissue and gene therapy products, a rapidly growing area of medical innovation. This timely regulatory co-operation will help strengthen regulatory capabilities and responsiveness in both countries, while maintaining robust standards of safety, quality and efficacy. Refer to Annex for photos.

4        HSA and NMPA share a longstanding bilateral relationship that has been progressively strengthened through a series of exchanges spanning more than 20 years, since the first MOU signed on 12 September 2003 with China's State Food and Drug Administration, known today as NMPA. This stronger collaboration also reinforces Singapore’s position as a trusted and globally collected regulatory hub for healthcare innovation. Through fostering this partnership, the MOU may create new opportunities for the industry, researchers and innovators seeking to develop and bring new and innovative products to both the markets. Presently, there are approximately 35 medicines and over 1,000 medical devices manufactured in China approved by HSA.

5        Adjunct Professor (Dr) Raymond Chua, Chief Executive Officer of HSA, said: “This renewed MOU reflects the strong and enduring partnership between HSA and NMPA, and our shared commitment to enabling innovation while safeguarding public health. By expanding our collaboration into new and emerging areas such as cell, tissue and gene therapy products, and strengthening cooperation to explore facilitative regulatory pathways, we hope to create a more agile and forward-looking regulatory environment to better respond to the rapidly evolving health products landscape, and bring safe and effective innovative products to benefit patients more quickly.” 

HEALTH SCIENCES AUTHORITY
SINGAPORE
12 MAY 2026

ANNEX

From left: Adjunct Professor (Dr) Raymond Chua, Chief Executive Officer of the Health Sciences Authority, Singapore and Mr Huang Guo, Commissioner of the National Medical Products Administration, China.

Adjunct Professor (Dr) Raymond Chua, Chief Executive Officer of the Health Sciences Authority, Singapore, sixth from left and Mr Huang Guo, Commissioner of the National Medical Products Administration, China, seventh from left, with delegates from HSA Singapore and NMPA China.

All photos are to be credited to the National Medical Products Administration, China.